VectivBio Holding AG
VECTDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Apraglutide
Short Bowel Syndrome
FE203799
SBS - Short Bowel Syndrome
FE203799 GLP-2 analogue
Short Bowel Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Apraglutide | Phase 3 | Short Bowel Syndrome | - | - |
FE203799 | Phase 2 | SBS - Short Bowel Syndrome | - | - |
FE203799 GLP-2 analogue | Phase 2 | Short Bowel Syndrome | - | - |
Frequently asked questions
What is in VectivBio Holding AG's drug pipeline?→
CatalystAlert tracks 3 drug candidates in VectivBio Holding AG's (VECT) pipeline across Phase 3, Phase 2. Its lead program is Apraglutide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VectivBio Holding AG's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for VectivBio Holding AG (VECT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VECT biotech catalysts?→
Add VECT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VectivBio Holding AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.